Copyright: ©Author(s) 2026.
World J Diabetes. Jun 15, 2026; 17(6): 121606
Published online Jun 15, 2026. doi: 10.4239/wjd.121606
Published online Jun 15, 2026. doi: 10.4239/wjd.121606
Figure 1 Changes of hemoglobin and serum creatinine.
A: The changes of hemoglobin (Hb) were showed in during hospitalization, Hb rose to 84 g/L; B: Serum creatinine decreased gradually to 147.8 μmol/L after chemotherapy. The patient was admitted to the hospital on July 13, 2025. A chemotherapy began to be carried out on August 30, 2025. Hb: Hemoglobin; CREA: Creatinine; eGFR: Estimated glomerular filtration rate.
Figure 2 Bone marrow obtained before the initiation of chemotherapy regimens.
A: Haematoxylin and eosin (H&E) staining (× 40); B: H&E staining (× 100); C-F: Immunohistochemical staining for CD38 (× 100; C), CD138 (× 100; D), lambda (× 100; E), and kappa (× 100; F).
Figure 3 Color fundus photography of the patient.
A: Left eye; B: Right eye. Both images demonstrate characteristic features of proliferative diabetic retinopathy, including retinal hemorrhages, exudates, and neovascularization.
- Citation: Li GZ, Liu JY, Hao HY, Zhou H. Clinical mismatches leading to the misdiagnosis of multiple myeloma as diabetic nephropathy: A case report. World J Diabetes 2026; 17(6): 121606
- URL: https://www.wjgnet.com/1948-9358/full/v17/i6/121606.htm
- DOI: https://dx.doi.org/10.4239/wjd.121606